Portal de Periódicos da CAPES

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

2019; National Academy of Sciences; Volume: 116; Issue: 19 Linguagem: Inglês

10.1073/pnas.1819745116

1091-6490

Jie Xu, Lijuan Chen, Shuangshuang Yang, Yan Sun, Wen Wu, Yuanfang Liu, Ji Xu, Yan Zhuang, Wu Zhang, Xiangqin Weng, Jing Wu, Yan Wang, Jin Wang, Hua Yan, Wenbin Xu, Hua Jiang, Juan Du, Xiaoyi Ding, Biao Li, Junmin Li, Weijun Fu, Jiang Zhu, Li Zhu, Chen Zhu, Xiao-Hu Fan, Jian Hou, Jianyong Li, Jian‐Qing Mi, Sai‐Juan Chen,

Virus-based gene therapy research

Significance Multiple myeloma (MM) is one of the most common hematological malignancies. Developing an effective treatment strategy for refractory/relapsed (R/R) MM represents a major challenge. In this trial, 17 R/R MM patients, who had previously experienced multiple lines of treatments, received a chimeric antigen receptor modified T (CAR T) cell preparation targeting two epitopes of BCMA, and a remarkable overall response of 88.2% was achieved. This work confirms the feasibility and importance of CAR T cell therapy in the treatment of patients with R/R MM. Meanwhile, the adverse events encountered in this study are analyzed, providing a reference for other studies. We also suggest that CAR T treatment can eventually be combined with other effective therapeutics to treat newly diagnosed MM for achieving a better result in future trials.